ClinicalTrials.gg
RecruitingNCT06787612Updated Nov 6, 2026

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

A Phase 2 interventional study of Ubamatamab and Bevacizumab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Regeneron Pharmaceuticals. Recruiting at 56 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 6, 2026Enrollment updatedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 276 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
145th of 1,499
397 · median 47
Started
2025
with 76 others
Phase 2
485 of 1,780
53 open now
Primary completion
2028-06
later than 309 of 450 live
Registered
1,660th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 145th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 77 that started in 2025, is one of 485 in phase 2, reaches primary completion later than 309 of the 450 other live ones, and was the 1,660th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

276 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

271 more — sign in →

All 276 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer.

The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug and its experimental combinations
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Keywords

  • Cancer of the Fallopian Tube
  • Cancer of the Ovary
  • Fallopian Tube Carcinoma
  • Fallopian Tube Neoplasm
  • Fallopian Tube Neoplasms
  • Ovarian Carcinoma
  • Ovarian Neoplasms
  • Peritoneal Cancer
  • Peritoneal Neoplasms
  • Platinum Resistance
  • PPC
  • Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
  2. Must have progression on prior therapy documented radiographically and must have at least 1 (not previously irradiated) that can be accurately measured by 1.1
  3. (ECOG) performance status of 0 or 1
  4. Adequate organ and bone marrow function, as described in the protocol
  5. Platinum-Resistant Ovarian Cancer, as described in the protocol

Key Exclusion Criteria:

  1. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s)
  2. Documented allergic or acute reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s)
  3. Another that is progressing or requires active treatment, as described in the protocol
  4. Untreated or active Central Nervous System (CNS) , or carcinomatous meningitis, as described in the protocol
  5. Uncontrolled infections including but not limited to , or infection, or diagnosis of immunodeficiency
  6. Moderate to large or ascites, as described in the protocol
  7. Bowel obstruction within last 3 months or current need for parenteral nutrition

NOTE: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
397 participants (estimated)

Study arms

  • Experimental
    Arm A1

    Drug: Ubamatamab · Drug: Sarilumab

  • Experimental
    Arm A2

    Drug: Ubamatamab · Drug: Sarilumab

  • Experimental
    Arm B

    Drug: Ubamatamab · Drug: Bevacizumab · Drug: Sarilumab

  • Experimental
    Arm C

    Drug: Ubamatamab · Drug: Cemiplimab · Drug: Fianlimab · Drug: Sarilumab

  • Experimental
    Arm D

    Drug: Ubamatamab · Drug: PLD · Drug: Sarilumab

  • Experimental
    Arms E1/E2

    Drug: Ubamatamab · Drug: Sarilumab · Drug: REGN10597

  • Experimental
    Arm Fa

    Drug: Ubamatamab

  • Experimental
    Arm Ga

    Drug: Ubamatamab · Drug: Sarilumab

  • Experimental
    Arm Fb

    Drug: Ubamatamab · Drug: Bevacizumab

  • Experimental
    Arm Gb

    Drug: Ubamatamab · Drug: Bevacizumab · Drug: Sarilumab

Interventions

  • Administered per the protocol

    Also known as: REGN4018

  • Administered per the protocol

    Also known as: Avastin®

  • Administered per the protocol

    Also known as: Libtayo®, REGN2810

  • Administered per the protocol

    Also known as: REGN3767

  • DrugPLD

    Administered per the protocol

    Also known as: Doxil®, Pegylated liposomal doxorubicin

  • Administered per the protocol

    Also known as: Kevzara®, REGN88, SAR153191

  • DrugREGN10597

    Administered per the protocol

    Also known as: PD-1-IL2Ra-IL2 immunotherapy

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment

    Time frame: Up to 3 years

Secondary outcomes

  1. Cancer Antigen (CA) -125 response by Gynecologic Cancer Intergroup (GCIG) Criteria

    Time frame: Up to 3 years

  2. Complete Response (CR) rate by RECIST 1.1

    Time frame: Up to 3 years

  3. Disease Control Rate (DCR) by RECIST 1.1

    Time frame: Up to 3 years

  4. Duration of Response (DOR) by RECIST 1.1

    Time frame: Up to 3 years

  5. Progression-Free Survival (PFS) by RECIST 1.1

    Time frame: Up to 3 years

  6. Occurrence of Grade ≥ 2 Cytokine Release Syndrome (CRS) by Lee criteria

    Time frame: Up to 3 years

  7. Treatment-Emergent Adverse Events (TEAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Up to 3 years

  8. TEAEs by Lee criteria

    Time frame: Up to 3 years

  9. Concentration of ubamatamab in serum

    Time frame: Up to 3 years

  10. Concentration of fianlimab in serum

    Time frame: Up to 3 years

  11. Concentration of REGN10597 in serum

    Time frame: Up to 3 years

  12. Occurrence of Anti-Drug Antibodies (ADA) to ubamatamab

    Time frame: Up to 3 years

  13. Magnitude of ADA to ubamatamab

    Time frame: Up to 3 years

  14. Occurrence of ADA to fianlimab

    Time frame: Up to 3 years

  15. Magnitude of ADA to fianlimab

    Time frame: Up to 3 years

  16. Occurrence of ADA to cemiplimab

    Time frame: Up to 3 years

  17. Magnitude of ADA to cemiplimab

    Time frame: Up to 3 years

  18. Occurrence of ADA to REGN10597

    Time frame: Up to 3 years

  19. Magnitude of ADA to REGN10597

    Time frame: Up to 3 years

07

Study locations

56 of 56 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 37 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 22, 2025
StartActual
May 28, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
297→397
Nov 6, 2026
Interventions
Arms added: Arm Fa·Arm Ga·Arm Fb·Arm Gb
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Enrollment 297→397
    Interventions Arms added: Arm Fa·Arm Ga·Arm Fb·Arm Gb
    + 5 other changes: verification date, description, conditions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06787612
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
May 28, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubamatamab

Start the discussion